Oct. 15, 2020 Vandana Singh, SA News Editor
Boston Scientific fell (BSX -4.0%), after reporting that its Scope II trial showed Acurate Neo structural heart valves failed to demonstrate non-inferiority when compared to Medtronic’s CoreValve Evolut. Results were announced during the TCT 2020 Investor Update
Total 796 patients aged 75 years or older with symptomatic severe aortic stenosis and an indication for transfemoral TAVR were recruited.
The trial missed the primary endpoint of composite of all-cause mortality or all stroke at 1 year. The primary efficacy endpoint, powered for superiority, was new permanent pacemaker implantation at 30 days. Secondary endpoints included clinical efficacy and safety endpoints at 30 days and 12 months.
In the intention-to-treat analysis, death or stroke at one year was 15.8% in the Acurate neo group compared to 13.9% in the CoreValve Evolut group, for per-protocol analysis it was 15.3% vs. 14.3%.
Noninferiority of the Acurate neo was not met for the primary endpoint in the intent-to-treat analysis, while it was met in the per-protocol analysis.
Acurate Neo2 estimated approval and U.S. launch is 2024.
Successful Trading is the art of minimizing long term risk and maximizing capital allocation.
Recent BSX News
- U.S. Futures Display Mixed Results Amid Earnings, WTI and Brent Crude Prices Dip in June Futures Trading • IH Market News • 04/24/2024 11:31:20 AM
- Boston Scientific Announces Results for First Quarter 2024 • PR Newswire (US) • 04/24/2024 10:30:00 AM
- Boston Scientific Initiates NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter and FARAVIEW™ Software Module • PR Newswire (US) • 04/08/2024 04:00:00 AM
- Boston Scientific Announces Conference Call Discussing First Quarter 2024 Results • PR Newswire (US) • 04/01/2024 12:00:00 PM
- Boston Scientific Receives FDA Approval for the AGENT™ Drug-Coated Balloon • PR Newswire (US) • 03/01/2024 11:55:00 AM
- Boston Scientific Announces Completion of €2.0 Billion Offering of Senior Notes • PR Newswire (US) • 02/27/2024 09:15:00 PM
- Boston Scientific Announces Pricing of €2.0 Billion of Senior Notes • PR Newswire (US) • 02/23/2024 02:27:00 AM
- Boston Scientific to Participate in TD Cowen's 44th Annual Health Care Conference • PR Newswire (US) • 02/05/2024 01:00:00 PM
- Boston Scientific Announces Results for Fourth Quarter and Full Year 2023 • PR Newswire (US) • 01/31/2024 11:30:00 AM
- U.S. Futures Waver Ahead of Fed Decision Amid Mixed Corporate Earnings; Oil Prices Slide • IH Market News • 01/31/2024 11:29:30 AM
- Boston Scientific Receives FDA Approval for FARAPULSE™ Pulsed Field Ablation System • PR Newswire (US) • 01/31/2024 11:25:00 AM
- Rowley Law PLLC is Investigating Proposed Acquisition of Axonics, Inc. • PR Newswire (US) • 01/08/2024 09:55:00 PM
- Axonics Shares Climb 20% After Acquisition by Boston Scientific • Dow Jones News • 01/08/2024 04:36:00 PM
- Boston Scientific To Acquire Axonics For About $3.7 Billion • Dow Jones News • 01/08/2024 12:41:00 PM
- Axonics Announces Definitive Agreement to be Acquired by Boston Scientific • Business Wire • 01/08/2024 12:00:00 PM
- Boston Scientific Announces Agreement to Acquire Axonics, Inc. • PR Newswire (US) • 01/08/2024 12:00:00 PM
- Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results • PR Newswire (US) • 01/05/2024 01:00:00 PM
- Boston Scientific Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation • PR Newswire (US) • 12/28/2023 09:00:00 PM
- Boston Scientific Closes Acquisition of Relievant Medsystems, Inc. • PR Newswire (US) • 11/17/2023 02:00:00 PM
- Boston Scientific to Participate in Stifel's 2023 Healthcare Conference • PR Newswire (US) • 11/01/2023 12:00:00 PM
- BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR THIRD QUARTER 2023 • PR Newswire (US) • 10/26/2023 10:30:00 AM
- Microcap Offers Unique Opportunity for Investors In $10 Billion SCI Industry • AllPennyStocks.com • 10/25/2023 09:18:00 PM
- Boston Scientific Gets Positive Results for Heart-Failure Device • Dow Jones News • 10/25/2023 07:32:00 PM
- Boston Scientific AGENT™ Drug-Coated Balloon Demonstrates Superiority to Uncoated Balloon Angioplasty in the AGENT IDE Trial • PR Newswire (US) • 10/25/2023 06:29:00 PM
- REAL-PE Study Demonstrates Statistically Significant Lower Major Bleeding Rates with the EKOS™ Endovascular System Compared to Mechanical Thrombectomy Device for Treatment of Pulmonary Embolism • PR Newswire (US) • 10/24/2023 07:18:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM